Why RemMedy Premium costs €6.99 today – and may cost more tomorrow

The last post was about why we chose a one-time purchase over a subscription. The logical next question: why €6.99, of all numbers? Why not €2.99? Why not €19.99? And will it stay that way?

The honest answer: €6.99 is our introductory price. We're deliberately going in low to keep the barrier small, and we think it's realistic that the price will go up later. Anyone who buys now locks in their price – and gets all future features for free, forever. Here's the full story.

What comparable apps cost

Medication apps with a Premium tier are almost always sold as subscriptions. The total over time often isn't immediately visible. A rough snapshot (as of 2026, end-user prices vary by region):

• Medisafe Premium – about $4.99/month or around $44.99/year. Over three years that's roughly $135–180.
• Round Health and similar apps – monthly prices in the €4–8 range, some with annual discounts.
• Mediteo, MyTherapy and other free offerings – price 0, but funded through insurance partnerships (sometimes tied to data sharing) or pharma collaborations.
• Apple Health-based apps – mostly free, but iOS only and locked into the Apple ecosystem.

Over three years of usage, typical subscription apps mean $100–180 – for a feature set that barely changes in that time. RemMedy: €6.99, once, done. That's a deliberate choice against the „keep billing long-term users forever" model.

Why we're starting low

A product without a known brand has two barriers at first contact: trust and price. We work on trust through transparent communication, a local data model, and open architecture. On price we can make it easy: a number you pay without thinking after the 7-day trial shows you the app is useful.

€6.99 is set below many impulse-buy thresholds – but high enough to let us expect we can fund the app if a small, stable base of buyers builds up.

Why the price will probably go up later

We've been expanding the feature set continuously since the first release. The changelog lists the milestones: Wear OS, monthly review, diary, inventory management. With every major block, the value Premium offers grows – and so do the costs we carry for support, Play Store fees, test devices, and development time.

Our expectation: Premium will get more expensive later, probably toward €9.99 or €12.99. No specific date, no specific number – just the clear expectation that €6.99 is an introductory price. We're saying this now so nobody feels in a year that we raised prices behind their back.

What this means for buyers

Here's the core of our promise:

• Anyone who pays €6.99 today keeps Premium at today's scope – for life.
• All future Premium features are included in the one-time purchase. If we introduce, say, family sharing or a doctor-portal export next year, everyone who already bought gets it without extra cost.
• A price hike affects new buyers only. Google Play technically ensures that already-bought IAPs continue unchanged.

This isn't a PR trick – it's a consequence of the one-time model. With a subscription, we'd have the theoretical option to raise the price yearly and force users to pay up or leave. With a one-time purchase, we simply don't.

A brief indie detour

RemMedy isn't a VC-backed startup. There are no investors, no growth targets, no exit plan. The app is built by 70six – a small software studio in Germany. That has consequences for pricing that would be unthinkable in a team with outside capital:

• No hockey-stick pressure. We don't have to grow 30% every quarter. We have to cover development time and can take a little longer on a feature if it matters.
• No data partnerships. We don't fund ourselves via pharma deals or research institutes buying anonymized data. Offline-first makes that technically impossible anyway – and we'd have no interest in it.
• No „free forever" tier that eventually gets pulled. RemMedy's free tier is part of our business model, not an acquisition trap. It stays.
• Direct support. If you send us feedback, it doesn't land with an outsourced vendor. That's possible because we run one app, not five at the same time.

Why we're making this transparent

We could have left the price at €6.99 and briefly posted „due to new features, the price is going up" when the time came. That's what most vendors do. The catch: there are always some users who feel blindsided – rightly, because nobody ever mentioned a raise could come.

We'd rather you know now: €6.99 is our introductory price. We'll likely raise it. If you buy now you lock in your price and get everything future added in. It's not a time-pressure sales trick – it's the logical consequence of what we actually plan to do.

If you're going to use the app anyway: the cheapest moment is now. If you're still looking, the pricing page has all the details, the manual shows the features, and the free tier runs forever – including after a future price increase.